Skip to content
Articles by Xueming Wu in JoVE
-
MR Imaging Molecolare del cancro alla prostata con un piccolo Molecular CLT1 Peptide mirato di contrasto agente
Xueming Wu1, Daniel Lindner2, Guan-Ping Yu1, Susann Brady-Kalnay3, Zheng-Rong Lu1
1Department of Biomedical Engineering, Case Western Reserve University, 2Department of Translational Hematology & Oncology Research, Cleveland Clinic, Case Western Reserve University, 3Department of Molecular Biology & Microbiology, Case Western Reserve University
Per dimostrare imaging molecolare del cancro RM con un piccolo peptide mirato MRI mezzo di contrasto specifico alle proteine plasmatiche coagulato in stroma tumorale in un modello di cancro alla prostata del mouse.
Other articles by Xueming Wu on PubMed
-
-
-
-
-
-
-
-
-
-
Synthesis and Evaluation of Nanoglobular Macrocyclic Mn(II) Chelate Conjugates As Non-gadolinium(III) MRI Contrast Agents
Bioconjugate Chemistry.
May, 2011 |
Pubmed ID: 21473650 Because of the recent observation of the toxic side effects of Gd(III) based MRI contrast agents in patients with impaired renal function, there is strong interest on developing alternative contrast agents for MRI. In this study, macrocyclic Mn(II) chelates were conjugated to nanoglobular carriers, lysine dendrimers with a silsesquioxane core, to synthesize non-Gd(III) based MRI contrast agents. A generation 3 nanoglobular conjugate of Mn(II)-1,4,7-triaazacyclononane-1,4,7-triacetate-GA amide (G3-NOTA-Mn) was also synthesized and evaluated. The per ion T(1) and T(2) relaxivities of G2, G3, G4 nanoglobular Mn(II)-DOTA monoamide conjugates decreased with increasing generation of the carriers. The T(1) relaxivities of G2, G3, and G4 nanoglobular Mn(II)-DOTA conjugates were 3.3, 2.8, and 2.4 mM(-1) s(-1) per Mn(II) chelate at 3 T, respectively. The T(1) relaxivity of G3-NOTA-Mn was 3.80 mM(-1) s(-1) per Mn(II) chelate at 3 T. The nanoglobular macrocyclic Mn(II) chelate conjugates showed good in vivo stability and were readily excreted via renal filtration. The conjugates resulted in much less nonspecific liver enhancement than MnCl(2) and were effective for contrast-enhanced tumor imaging in nude mice bearing MDA-MB-231 breast tumor xenografts at a dose of 0.03 mmol Mn/kg. The nanoglobular macrocyclic Mn(II) chelate conjugates are promising nongadolinium based MRI contrast agents.
-
-
-
-
-
-
-
-
Isolation, Identification and Pharmacokinetic Analysis of Fructosyl Puerarins from Enzymatic Glycosylation
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences.
Sep, 2013 |
Pubmed ID: 23948238 A method of using high-speed counter-current chromatography (HSCCC) was established for preparative isolation and purification of puerarin glycosides from the crude sample after enzymatic glycosylation of puerarin. Four fructosyl puerarins were successfully purified for the first time by HSCCC with a two-phase-solvent system composed of n-butanol-acetic acid-water (4:1.5:6, v/v/v). A total of 5mg of puerarin (1), 20mg of β-d-fructofuranosyl-(2→6)-puerarin (2), 41mg of β-d-difructofuranosyl-(2→6)-puerarin (3), 18mg of β-d-trifructofuranosyl-(2→6)-puerarin (4) and 15mg β-d-tetrafructofuranosyl-(2→6)-puerarin (5) were obtained in one-step separation from 100mg of the crude sample with purities of 98.5%, 98.3%, 98.9%, 97.8%, 97.5% and 97.2%, respectively. Among them, compounds 2-5 are novel compounds, and their chemical structures were identified by HRMS, (1)H NMR, (13)C NMR and 2D NMR. Pharmacokinetic analysis showed that β-d-fructofuranosyl-(2→6)-puerarin (2) was able to maintain higher plasma concentrations and have a longer mean residence time in the blood than puerarin.
Get cutting-edge science videos from JoVE sent straight to your inbox every month.